Qurient Co., Ltd.
- Country
- 🇰🇷South Korea
- Ownership
- Public
- Established
- 2008-07-02
- Employees
- 32
- Market Cap
- -
- Website
- http://www.qurient.com
Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor Q702 in Combination With Pembrolizumab in Patients With Selected Advanced Solid Tumors
- Conditions
- Esophageal CancerGastric CancerHepatocellular CancerCervical Cancer
- Interventions
- Biological: Pembrolizumab
- First Posted Date
- 2022-06-30
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- Qurient Co., Ltd.
- Target Recruit Count
- 120
- Registration Number
- NCT05438420
- Locations
- 🇰🇷
CHA Bundang Medical Center, Seongnam-si, Korea, Republic of
🇰🇷Asan Medical Center, Seoul, Korea, Republic of
🇰🇷Samsung Medical Center, Seoul, Korea, Republic of
Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors
- Conditions
- Metastatic CancerAdvanced Cancer
- Interventions
- First Posted Date
- 2022-05-27
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- Qurient Co., Ltd.
- Target Recruit Count
- 130
- Registration Number
- NCT05394103
- Locations
- 🇺🇸
University of Southern California, Los Angeles, California, United States
🇺🇸Northwestern University, Chicago, Illinois, United States
🇺🇸Mary Crowley Cancer Research, Dallas, Texas, United States
A Phase 2 Study to Evaluate Biomarker Change, Efficacy, Pharmacokinetics, Safety and Tolerability of Telacebec (Q203) in Covid-19 Patients
- Conditions
- COVID-19 Virus Infection
- Interventions
- Drug: COVID-19 Standard of care
- First Posted Date
- 2021-04-19
- Last Posted Date
- 2022-03-02
- Lead Sponsor
- Qurient Co., Ltd.
- Target Recruit Count
- 1
- Registration Number
- NCT04847583
- Locations
- 🇿🇦
Chris Hani Baragwanath Academic Hospital, Soweto, Gauteng, South Africa
🇿🇦KwaPhila Health Solutions, Durban, Kwa-Zula Natal, South Africa
🇿🇦TASK Eden, George, Western Cape, South Africa
Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumor
- Conditions
- Solid TumorAdvanced CancerMetastatic Cancer
- Interventions
- First Posted Date
- 2020-12-01
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Qurient Co., Ltd.
- Target Recruit Count
- 78
- Registration Number
- NCT04648254
- Locations
- 🇺🇸
University of Southern California, Los Angeles, California, United States
🇺🇸Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸Northwestern University, Chicago, Illinois, United States
Safety and Efficacy Study of Q301 in Mild to Moderate Adolescents and Adults Atopic Dermatitis Patients
- Conditions
- Atopic Dermatitis
- Interventions
- Drug: VehicleDrug: Q301 Cream
- First Posted Date
- 2018-06-27
- Last Posted Date
- 2020-04-24
- Lead Sponsor
- Qurient Co., Ltd.
- Target Recruit Count
- 258
- Registration Number
- NCT03571620
- Locations
- 🇺🇸
Wake Forest School of Medicine Department of Dermatology, Winston-Salem, North Carolina, United States
A Phase 2 Study to Evaluate Early Bactericidal Activity, Safety, Tolerability, and Pharmacokinetics of Multiple Oral Doses of Telacebec (Q203)
- Conditions
- Treatment-naïve, Sputum Smear-positive Patients With Drug-sensitive Pulmonary TB
- Interventions
- Drug: Rifafour e-275
- First Posted Date
- 2018-06-20
- Last Posted Date
- 2019-09-10
- Lead Sponsor
- Qurient Co., Ltd.
- Target Recruit Count
- 60
- Registration Number
- NCT03563599
- Locations
- 🇿🇦
TASK Applied Science, Cape Town, South Africa
🇿🇦UCT Lung Institute, Cape Town, South Africa
A Dose-Escalation Study to Evaluate Safety, Tolerability and Pharmacokinetics of Multiple Doses of Q203 in Normal Healthy Male and Female Volunteers
- First Posted Date
- 2016-08-08
- Last Posted Date
- 2018-05-14
- Lead Sponsor
- Qurient Co., Ltd.
- Target Recruit Count
- 47
- Registration Number
- NCT02858973
A Dose-Escalation Study to Evaluate Safety, Tolerability and Pharmacokinetics of Single Doses of Q203 in Normal, Healthy, Male and Female Volunteers
- First Posted Date
- 2015-08-21
- Last Posted Date
- 2016-12-06
- Lead Sponsor
- Qurient Co., Ltd.
- Target Recruit Count
- 56
- Registration Number
- NCT02530710
Safety and Efficacy Study of Q301 in Moderate to Severe Atopic Dermatitis Patients
- Conditions
- Moderate to Severe Atopic Dermatitis
- Interventions
- Drug: Q301 CreamDrug: Placebo
- First Posted Date
- 2015-04-24
- Last Posted Date
- 2016-12-06
- Lead Sponsor
- Qurient Co., Ltd.
- Target Recruit Count
- 57
- Registration Number
- NCT02426359